Brought to you by 
TopoTarget to acquire Apoxis for €14.5mm in stock
03 May 2007
Executive Summary
TopoTarget has announced that it will issue €14.5mm ($19.78mm) of its own stock to strengthen its cancer portfolio through the acquisition of oncology therapeutics company Apoxis SA.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com